Research map: Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer

Back to the article

Papers in this map

  1. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy · Catherine Alix‐Panabières · 2016 · 1425 citations · Cited by this paper
  2. Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial · 2026 · Related
  3. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer · Jeanne Tie · 2022 · 1082 citations · Cited by this paper
  4. Early-onset biliary tract cancers: clinical and molecular insights · 2026 · Related
  5. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer · Thomas Reinert · 2019 · 1054 citations · Cited by this paper
  6. Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer · 2026 · Related
  7. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial · Ángela Lamarca · 2021 · 787 citations · Cited by this paper
  8. A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE · 2026 · Related
  9. ctDNA-based molecular residual disease and survival in resectable colorectal cancer · Yoshiaki Nakamura · 2024 · 250 citations · Cited by this paper
  10. Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study · 2026 · Related
  11. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study · John Bridgewater · 2022 · 216 citations · Cited by this paper
  12. Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study · 2026 · Related
  13. Current and emerging therapies for advanced biliary tract cancers · Audrey E. Kam · 2021 · 176 citations · Cited by this paper
  14. Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer · 2026 · Related
  15. ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer · Thomas B. Powles · 2025 · 143 citations · Cited by this paper
  16. The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors · 2026 · Related
  17. Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma · James R. Black · 2025 · 106 citations · Cited by this paper
  18. BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer · 2026 · Related
  19. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer · Alessandro Rizzo · 2021 · 89 citations · Cited by this paper
  20. Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands · 2026 · Related
  21. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial · Jeanne Tie · 2025 · 76 citations · Cited by this paper
  22. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer · Sohyun Hwang · 2024 · 55 citations · Cited by this paper
  23. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma · Gregory P. Botta · 2024 · 44 citations · Cited by this paper
  24. Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma · Changhoon Yoo · 2024 · 38 citations · Cited by this paper
  25. Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study · Aziz Zaanan · 2025 · 36 citations · Cited by this paper
  26. Serum carcinoembryonic antigen and carbohydrate antigen 19-9 as preoperative diagnostic biomarkers of extrahepatic bile duct cancer · Hyeong Seok Kim · 2021 · 17 citations · Cited by this paper
  27. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy · Dae‐Won Lee · 2017 · 11 citations · Cited by this paper
  28. Circulating tumor DNA analysis guiding adjuvant treatment in resected stage III cholangiocarcinoma: a case report · James B. Yu · 2024 · 11 citations · Cited by this paper
  29. Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer · Stacey A. Cohen · 2025 · 8 citations · Cited by this paper

Source: OpenAlex (CC0)